Literature DB >> 10462535

DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells.

W Nieves-Neira1, M I Rivera, G Kohlhagen, M L Hursey, P Pourquier, E A Sausville, Y Pommier.   

Abstract

2, 5-bis(5-Hydroxymethyl-2-thienyl)furan (NSC 652287), is a representative of a series of thiophene derivatives that exhibit potent and selective antitumor activity against several tumor cell lines in the National Cancer Institute Anticancer Drug Screen. NSC 652287 has noticeable activity for the renal cell lines and produces cures in certain corresponding xenografts. The cellular mechanisms of action of NSC 652287 were therefore investigated in this study in greater detail. The most sensitive renal carcinoma cell line, A498, exhibited cell cycle arrest in G(0)-G(1) and G(2)-M at 10 nM NSC 652287, with increased p53 and p21(WAF1) protein. At higher concentrations, NSC 652287 still induced p53 elevation but with p21(WAF1) reduction and massive apoptosis. These results collectively suggested that NSC 652287 induced DNA damage. Using alkaline elution techniques, we found that NSC 652287 induced both DNA-protein and DNA-DNA cross-links with no detectable DNA single-strand breaks. These DNA-protein cross-links (DPC) persisted for at least 12 h after drug removal and their frequency was correlated with cytotoxicity in the renal cell lines studied. The most sensitive cells (A498) produced the highest DPC followed by the cell line with intermediate sensitivity (TK-10). DPC were minimal in the two resistant cell lines, ACHN and UO-31. Nonetheless, a similar degree of DPC occurred at doses imparting equitoxic effects. These results indicate that DNA is a primary target for the novel and potent anticancer thiophene derivative, NSC 652287. NSC 652287 did not cross-link purified DNA or mammalian topoisomerase I suggesting the importance of active metabolite(s) for the cross-linking activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462535     DOI: 10.1124/mol.56.3.478

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  19 in total

1.  Specific RITA Modification Produces Hyperselective Cytotoxicity While Maintaining In Vivo Antitumor Efficacy.

Authors:  Brian D Peyser; Ann Hermone; Joseph M Salamoun; James C Burnett; Melinda G Hollingshead; Connor F McGrath; Rick Gussio; Peter Wipf
Journal:  Mol Cancer Ther       Date:  2019-07-24       Impact factor: 6.261

2.  Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis.

Authors:  Michael I Carr; Stephen N Jones
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

3.  The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Authors:  Ogan D Abaan; Eric C Polley; Sean R Davis; Yuelin J Zhu; Sven Bilke; Robert L Walker; Marbin Pineda; Yevgeniy Gindin; Yuan Jiang; William C Reinhold; Susan L Holbeck; Richard M Simon; James H Doroshow; Yves Pommier; Paul S Meltzer
Journal:  Cancer Res       Date:  2013-07-15       Impact factor: 12.701

Review 4.  p53-based cancer therapy.

Authors:  David P Lane; Chit Fang Cheok; Sonia Lain
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05-12       Impact factor: 10.005

Review 5.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

6.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

7.  Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia.

Authors:  Jun Yang; Afshan Ahmed; Evon Poon; Nina Perusinghe; Alexis de Haven Brandon; Gary Box; Melanie Valenti; Suzanne Eccles; Kasper Rouschop; Brad Wouters; Margaret Ashcroft
Journal:  Mol Cell Biol       Date:  2009-02-17       Impact factor: 4.272

Review 8.  MDM2, MDMX and p53 in oncogenesis and cancer therapy.

Authors:  Mark Wade; Yao-Cheng Li; Geoffrey M Wahl
Journal:  Nat Rev Cancer       Date:  2013-01-10       Impact factor: 60.716

Review 9.  Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

Authors:  Yuan Yuan; Yu-Min Liao; Chung-Tsen Hsueh; Hamid R Mirshahidi
Journal:  J Hematol Oncol       Date:  2011-04-20       Impact factor: 17.388

10.  Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1.

Authors:  A Ahmed; J Yang; A Maya-Mendoza; D A Jackson; M Ashcroft
Journal:  Cell Death Dis       Date:  2011-05-19       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.